Abstract:Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a variety of disease symptoms and an unpredictable clinical course. To improve treatment outcome, stratification based on immunological manifestations commonly seen in patients with SLE such as autoantibodies, type I interferon (IFN) signature and neutrophil extracellular trap (NET) release may help. It is assumed that there is an association between these immunological phenomena, since NET release induces IFN production and IFN induces autoantibody formation via B-cell activation. Here we studied the association between autoantibodies, the IFN signature, NET release, and clinical manifestations in patients with SLE. Methods: We performed principal component analysis (PCA) and hierarchical clustering of 57 SLE-related autoantibodies in 25 patients with SLE. We correlated each autoantibody to the IFN signature and NET inducing capacity. Results: We observed two distinct clusters: one cluster contained mostly patients with a high IFN signature. Patients in this cluster often present with cutaneous lupus, and have higher anti-dsDNA concentrations. Another cluster contained a mix of patients with a high and low IFN signature. Patients with high and low NET inducing capacity were equally distributed between the clusters. Variance between the clusters is mainly driven by antibodies against histones, RibP2, RibP0, EphB2, RibP1, PCNA, dsDNA, and nucleosome. In addition, we found a trend towards increased concentrations of autoantibodies against EphB2, RibP1, and RNP70 in patients with an IFN signature. We found a negative correlation of NET inducing capacity with anti-FcER (r = -0.530; p = 0.007) and anti-PmScl100 (r = -0.445; p = 0.03). Conclusion: We identified a subgroup of patients with an IFN signature that express increased concentrations of antibodies against DNA and RNA-binding proteins, which can be useful for further patient stratification and a more targeted therapy. We did not find positive associations between autoantibodies and NET inducing capacity. Our study further strengthens the evidence of a correlation between RNA-binding autoantibodies and the IFN signature.

Role of Nucleic Acid-Sensing Tlrs in Diverse Autoantibody Specificities and Anti-Nuclear Antibody-Producing B Cells

Differential role of nucleic acid-sensing toll-like receptors in autoantibody production. (44.29)

Endosomal TLR Signaling is Required for Anti-Nucleic Acid and Rheumatoid Factor Autoantibodies in Lupus

B cell autophagy mediates TLR7-dependent autoimmunity and inflammation

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

Genetic Complementation Results in Augmented Autoantibody Responses to Lupus-Associated Antigens.

Impact of TLR9 on Hyper-Responsive ITAM Signaling in a Mouse Model of SLE (47.24)

TLR9 restricts survival of anergic anti-DNA B cells in systemic lupus erythematosus yet is also required for their activation (BA4P.219)

The B cell response to both protein and nucleic acid antigens displayed on apoptotic cells are dependent on endosomal pattern recognition receptors

Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus

UNC93B1 variants underlie TLR7-dependent autoimmunity

Unc93B1 Biases Toll-like Receptor Responses to Nucleic Acid in Dendritic Cells Toward DNA- but Against RNA-sensing.

Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus

Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus

Autoantibody-dependent amplification of inflammation in SLE

Role of DNA/RNA sensors and contribution to autoimmunity

TLR9 Promotes Tolerance by Restricting Survival of Anergic Anti-DNA B Cells, Yet Is Also Required for Their Activation

Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus

Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.

Autoantibody Induction by DNA-Containing Immune Complexes Requires HMGB1 with the TLR2/MicroRNA-155 Pathway

Mitochondria Activity and CXCR4 Collaboratively Promote the Differentiation of CD11c+ B Cells Induced by TLR9 in Lupus